Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (91-100 of 471) with videos related to

Pageof 48
Sort By:
JACC. Heart Failure|March 7, 2015
Effect of ivabradine on early readmissions after hospitalization for worsening heart failureJeffrey S Borer, Michael Böhm, Ian Ford, et al.
International Journal of Cardiology|April 24, 2012
Trends in publications on stress-induced cardiomyopathyYangzhen Shao, Bjorn Redfors, Alexander R Lyon, et al.
BMJ Open|October 9, 2025
Economic evaluation of a person-centred care intervention with a digital platform and structured telephone support for people with chronic heart failure and/or chronic obstructive pulmonary disease: results from a randomised controlled trial in SwedenBenjamin P Harvey, Emmelie Barenfeld, Andreas Fors, et al.
Lakartidningen|May 20, 2006
[BNP or NT-proBNP should be analyzed in suspected heart failure. Guidelines for analysis and interpretation]Tomas Jernberg, Kurt Boman, Stefan James, et al.
Lakartidningen|September 23, 2015
[Stroke prophylaxis in atrial fibrillation: Choose new anticoagulants before warfarin]Ingmar Torstensson, Carina Blomström-Lundqvist, S Bertil Olsson, et al.
Journal of the American College of Cardiology|May 24, 2012
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Journal of the American College of Cardiology|May 20, 2017
Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?Ankeet S Bhatt, Adam D DeVore, Tracy A DeWald, et al.
JACC. Heart Failure|May 15, 2017
Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 YearsMilton Packer, Bertram Pitt, Jean-Lucien Rouleau, et al.
European Journal of Heart Failure|October 7, 2006
International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure SurveyMitja Lainscak, John G F Cleland, Mattie J Lenzen, et al.
The American Journal of Cardiology|December 17, 2013
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)Jeffrey S Borer, Michael Böhm, Ian Ford, et al.
Pageof 48

Showing results (91-100 of 471) with videos related to

Sort By:
Pageof 48
JACC. Heart Failure|March 7, 2015
Effect of ivabradine on early readmissions after hospitalization for worsening heart failureJeffrey S Borer, Michael Böhm, Ian Ford, et al.
International Journal of Cardiology|April 24, 2012
Trends in publications on stress-induced cardiomyopathyYangzhen Shao, Bjorn Redfors, Alexander R Lyon, et al.
BMJ Open|October 9, 2025
Economic evaluation of a person-centred care intervention with a digital platform and structured telephone support for people with chronic heart failure and/or chronic obstructive pulmonary disease: results from a randomised controlled trial in SwedenBenjamin P Harvey, Emmelie Barenfeld, Andreas Fors, et al.
Lakartidningen|May 20, 2006
[BNP or NT-proBNP should be analyzed in suspected heart failure. Guidelines for analysis and interpretation]Tomas Jernberg, Kurt Boman, Stefan James, et al.
Lakartidningen|September 23, 2015
[Stroke prophylaxis in atrial fibrillation: Choose new anticoagulants before warfarin]Ingmar Torstensson, Carina Blomström-Lundqvist, S Bertil Olsson, et al.
Journal of the American College of Cardiology|May 24, 2012
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) studyKarl Swedberg, Michel Komajda, Michael Böhm, et al.
Journal of the American College of Cardiology|May 20, 2017
Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?Ankeet S Bhatt, Adam D DeVore, Tracy A DeWald, et al.
JACC. Heart Failure|May 15, 2017
Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 YearsMilton Packer, Bertram Pitt, Jean-Lucien Rouleau, et al.
European Journal of Heart Failure|October 7, 2006
International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure SurveyMitja Lainscak, John G F Cleland, Mattie J Lenzen, et al.
The American Journal of Cardiology|December 17, 2013
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)Jeffrey S Borer, Michael Böhm, Ian Ford, et al.
Pageof 48